Select region:

Clinical trials located in

Tübingen

Tübingen city is located in Germany. Currently, 20 clinical trials are being conducted in this city.

Tübingen, nestled in southwest Germany, is a quintessential university town, home to the prestigious Eberhard Karls University, founded in 1477. This historic city is characterized by its picturesque half-timbered houses and winding cobblestone streets. The Neckar River gracefully flows through Tübingen, with the iconic Holderlin Tower standing guard. A unique tradition is the Stocherkahnrennen, an annual punt race that showcases the city’s vibrant student life. Tübingen also played a significant role in the Reformation and boasts a rich academic and cultural heritage, making it a focal point of German intellectual and cultural life.

  • CT-EU-00112349

    Testing New Therapies for Glioblastoma Brain Cancer

    Howdy there, partner! This here trial is called the GBM AGILE study, and it’s aiming to find better treatments for a type of brain cancer called glioblastoma. Now, glioblastoma is a real tough customer, but this study is taking a new approach by testing multiple therapies all at once, both for newly diagnosed cases and for those where the cancer has come back.

    The main goal is to find treatments that work better and can be matched to different types of glioblastoma. The study uses a fancy method called Bayesian response adaptive randomization to assign folks to different treatment arms based on how well those treatments are performing. The most important measure they’re looking at is overall survival – how long patients live after starting treatment.

    Some of the therapies being tested include drugs like temozolomide, lomustine, regorafenib, paxalisib, VAL-083, VT1021, and troriluzole. These come in different forms like capsules, tablets, or infusions, and the dosages and schedules vary depending on the drug. The study is set up so that new promising therapies can be added in, and ones that aren’t working so well can be removed as the trial goes on.

    FranceGermany
  • Testing the effectiveness of new drugs in the treatment of age-related macular degeneration

    The study is investigating a potential breakthrough in treating age-related vision loss, specifically neovascular age-related macular degeneration (nAMD). It introduces a novel therapy, OPT-302, and pairs it with Aflibercept, comparing this combination’s effectiveness against the standard treatment. Participants undergo a series of thorough eye examinations and treatments to monitor the progression of their vision health. The research aims to offer a clearer understanding of how these treatments can better manage and possibly improve vision for individuals dealing with nAMD, contributing valuable knowledge to the field of eye health care.

    AustriaBulgariaCzechiaDenmarkFranceGermanyGreeceHungaryItalyNetherlandsPolandSlovakiaSpainUnited Kingdom
  • Investigating efficacy and safety of new therapy in early-stage Parkinson’s disease

    This clinical trial aims to examine BIIB122, a new medication considered to potentially slow down the progression of early-stage Parkinson’s disease in patients aged between 30–80 years old. Participants will undergo treatment with either BIIB122 or a placebo equal in appearance but devoid of actual medicine. The trial’s routine includes a single daily medication intake for a timeframe between 48 and 144 weeks. To evaluate the medication’s efficacy, patients’ symptoms and their impact on everyday life will be observed using the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS). In addition to this, safety assessment of BIIB122 will be a main focus of the study. The trial treats this as a double-blind study, anonymizing whether a patient takes the BIIB122 drug or a placebo.

    AustriaFranceGermanyItalyNetherlandsPolandSpainUnited Kingdom
  • Studying efficacy of volrustomig for metastatic lung cancer

    The study compared two treatments for metastatic non-small cell lung cancer: volrustomig with chemotherapy and pembrolizumab with chemotherapy. Its purpose is to determine which combination is more effective and safer. Patients will be divided into two groups. One group will receive volrustomig and chemotherapy, and the other group will receive pembrolizumab and chemotherapy. The effectiveness of treatment in each group will then be tracked using imaging tests. In addition, a group of researchers will follow each participant until the end of the study to make sure the treatment is safe and tolerable.

    AustriaBelgiumCzechiaFranceGermanyHungaryItalyNetherlandsPolandSlovakiaSpainUnited Kingdom
  • Research on new medicine for advanced or metastatic lung cancer

    This study investigates a new medicine called JDQ443’s ability to combat advanced non-small cell lung cancer. It involves two groups based on their PD-L1 levels and mutations KRAS G12C. The study has two parts (called cohorts), each involving different people. The study is carried out in stages called ‘cycles’ which last for 21 days each. During the study, assessments will be conducted to evaluate the medicine’s effectiveness, and health monitoring will be implemented. This involves measuring factors such as the duration until disease progression and the length of survival post-treatment initiation.

    AustriaBelgiumBulgariaFranceGermanyGreeceHungaryItalyNetherlandsPortugalSpainUnited Kingdom
  • CT-EU-00041922

    Testing new medication for adult muscle inflammation treatment

    This study aims to test a medicine called Efgartigimod (EFG PH20 SC) for adults who are suffering from a disease called Idiopathic Inflammatory Myopathy (IIM), where muscles become inflamed for unknown reasons. This condition often falls into groups like dermatomyositis, immune-mediated necrotizing myopathy, or specific types of polymyositis. The trial wants to compare how good the medicine is against a placebo. The researchers will look at how much people’s symptoms improve and whether there are any side effects. The test is going to be carried out in many locations and will involve people over 18 years old.

    AustriaBelgiumBulgariaDenmarkFranceGermanyGreeceHungaryItalyNetherlandsPolandPortugalSpainSwedenUnited Kingdom
  • Testing new treatment for Geographic Atrophy treatment

    This research study pertains to a condition affecting the eyes known as Geographic Atrophy (GA), stemming from the aging process (Age-related Macular Degeneration). The investigation aims to assess the potential efficacy of a new drug (JNJ-81201887), administered through intraocular injection, in improving the aforementioned condition. A comparative analysis will be conducted between individuals receiving the drug and those subjected to a placebo procedure (a simulated intervention lacking an actual drug). Specialized photographs will be taken to quantify any alterations in the condition over an 18-month period. Additionally, observations will be made regarding changes in distant visual acuity, reading ability, and the requirement for aids during these activities over time. Ultimately, the study will examine the impact of the eye condition on daily activities.

    BelgiumCzechiaDenmarkGermanyHungaryItalyNetherlandsPolandPortugalSpainSwedenUnited Kingdom
  • Examining mometasone furoate role in treating long-lasting sinusitis

    This trial will study the effects of a drug called LYR-210 (Mometasone Furoate) on adults who have a long-term nose and sinus condition known as chronic rhinosinusitis (CRS). It focuses on the treatment’s effectiveness and safety over 24 weeks, comparing LYR-210 with a sham procedure. The study measures symptom changes, assessing impacts on nasal blockage, discharge, and facial pain. The trial is a significant step towards potentially offering relief to those suffering from persistent sinus challenges.

    BelgiumBulgariaGermanyHungaryPoland
  • Study of new potential drug impact on advanced solid tumors’ cancer

    This study investigates the potential of a drug called LOXO-435 (or LY3866288) for individuals with specific types of cancer, including urinary system cancers, contingent on the presence of a particular gene change, FGFR3. The primary objectives are to assess the safety profile, identify potential side effects, and evaluate the efficacy of the drug. Participation in the study may extend for up to two and a half years or longer. Unlike a ‘blind’ study, both doctors and participants are aware of who is receiving the drug. The study comprises two parts: firstly, determining the optimal dose, and subsequently administering that amount to participants. Various groups exist within the study, including those solely receiving LOXO-435 and another group combining it with an additional drug. Assessment of the drug’s effectiveness involves monitoring changes in symptoms related to the bladder and physical function.

    FranceGermanyNorwaySpainUnited Kingdom
  • Examining ultrasound-assisted and standard treatment for lung clots

    In this study, researchers want to compare two treatments for a disease called pulmonary embolism. This is a disease in which a blood clot blocks the vessels that supply blood to the lungs. The group of people taking part in the study will be randomly assigned to receive either blood-thinning medications alone (anticoagulation) or blood-thinning medications using a blood clot-dissolving device. The name of this device is the EkoSonic endovascular device. The research will continue for 12 months, and the health of the participants will be regularly monitored.

    AustriaFranceGermanyNetherlandsPolandUnited Kingdom
  • Study of nivolumab + relatlimab for new advanced melanoma cases

    The study explores the effects of combining Nivolumab and Relatlimab, given subcutaneously, in treating melanoma that hasn’t been treated before and can’t be surgically removed. The focus is on the medication levels in the blood and comparing the treatment’s impact on the disease with standard methods​​.

    AustriaBelgiumCzechiaFinlandFranceGermanyItalyNorwayPolandSpainSwedenUnited Kingdom
  • Study testing Ruxolitinib cream for Prurigo Nodularis treatment

    This study is testing a cream with Ruxolitinib to see if it’s safe and effective for people with a skin condition called Prurigo Nodularis (PN). The study has three main parts. In the first 12 weeks, participants will receive either the cream with Ruxolitinib or placebo (also known as vehicle-controlled) treatment. After that, all participants will receive the cream with Ruxolitinib for another 40 weeks. After that, there will be an extra 30 days to keep an eye on safety. The trial will measure success by checking if the cream can reduce itchiness. Treatment success will be evaluated by medical professionals, considering factors such as the number of skin nodules and the extent of redness and crusting in the condition’s severity.

    BelgiumFranceGermanyItalyNetherlandsPolandSpain
  • Continued study of ozanimod for severe Crohn’s Disease

    This research is about an extended study on the use of an oral medication named Ozanimod for people suffering from Crohn’s disease. Crohn’s disease can make the stomach and intestines really uncomfortable, causing swellings and pain. The main aim of this study is to check if this medicine, Ozanimod, is safe for intake and how effective it is in easing these uncomfortable feelings in the stomach. The researchers will rate patients’ illnesses using the Crohn’s Disease Activity Index (a measurement tool).

    BelgiumBulgariaCzechiaFranceGermanyHungaryItalyNetherlandsPolandPortugalRomaniaSlovakiaSpainUnited Kingdom
  • Testing Milvexian’s effectiveness in preventing repeat strokes

    This research trial, called LIBREXIA-STROKE, will test a medication called Milvexian on those who have recently had a stroke or a high-risk ‘mini-stroke’. In its 3rd testing phase, the study will involve a system where the patients won’t know whether they are receiving the actual drug or a substitute with no effect, referred to as a ‘placebo’, to maintain fairness. Milvexian is a medication that can potentially reduce the risk of having another stroke, and this trial aims to observe how effective it is in doing so. The trial will look at when the first stroke happens after starting the trial, if other major heart or limb diseases occur, or if strokes occur in the first 90 days.

    AustriaBelgiumBulgariaCzechiaDenmarkFinlandFranceGermanyHungaryItalyNetherlandsPolandPortugalRomaniaSlovakiaSpainSwedenUnited Kingdom
  • Deucravacitinib: A possible solution for active Sjögren’s Syndrome

    This research trial is all about figuring out if a medicine called Deucravacitinib is helpful and safe for adults living with a condition known as Sjgren’s Syndrome. In this study, everyone will be randomly placed into different groups. Some people will get the real medicine, while others will get a placebo. The whole purpose is to see if Deucravacitinib can improve the health of adults with Sjgren’s Syndrome.

    AustriaFranceGermanyHungaryPolandPortugalRomaniaSpainSweden
  • Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    AustriaCzechiaFranceItalyRomaniaSpainUnited Kingdom
  • Study on Baricitinib for Juvenile Idiopathic Arthritis treatment

    This research study focuses on evaluating the medication named Baricitinib in young people (from 1 to less than 18 years old) who are dealing with Juvenile Idiopathic Arthritis. This type of arthritis leads to painful and swollen joints. The study, in its third phase, is conducted at multiple locations. The primary goals are to assess the safety of this medicine for young individuals and to determine its effectiveness in managing their condition over the long term.

    DenmarkGermanyUnited Kingdom
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    AustriaBelgiumFrancePolandUnited Kingdom
  • Research of combination therapy for metastatic melanoma

    This study looks into a new test treatment for serious skin cancer. It’s a big study, happening in multiple places. It will look at two things: one, a drug called HBI-8000 (Tudicdinostat) taken together with another drug called Nivolumab, and two, just Nivolumab on its own. The main goal is to see which approach works better for patients. Patients who can take part are ones who haven’t tried specific cancer treatments before (PD-1 or PD-L1 inhibitors). However, young people or people with quickly worsening brain tumors can’t take part. The patients are picked based on whether a certain substance is present in their cancer cells (PD-L1 expression) and the LDH level that’s found in their blood.

    AustriaBelgiumCzechiaFranceGermanyItalySpainUnited Kingdom
  • Comparison of new treatment and standard care for lymphoma patients

    A new approach to treating Lymphoma, a type of cancer originating in cells constituting the body’s immune system, is being tested in this trial. Comparison is being made between a new treatment, referred to as MB-CART2019.1, and the presently conventional treatment. The MB-CART2019.1 therapy is designed to target the aberrant B cells responsible for this form of cancer. In the process of creating MB-CART2019.1, cells are extracted from the patient’s own body, modified in the laboratory to combat cancer, and subsequently reintroduced into the patient. Participants in this trial will receive either MB-CART2019.1 or the standard treatment. The standard treatment involves the use of a drug combination (rituximab, gemcitabine, oxaliplatin (R-GemOx) or bendamustine, rituximab (BR) + polatuzumab vedotin). The objective is to assess whether MB-CART2019.1 demonstrates superior efficacy compared to these conventional drugs. Patient progress will be closely monitored for approximately one year to evaluate their well-being.

    AustriaBelgiumCzechiaFranceGermanyHungaryItalyNetherlandsPolandSpainSweden

See more clinical trials in other cities in Germany:

.